SCHEMBL4401872

SCHEMBL4401872

CCc1cc(Nc2nccs2)nc(Cl)n1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SRC P12931 1/20 0.38
BTK Q06187 1/20 0.38
CSF1R P07333 1/20 0.37
LTK P29376 1/20 0.37
MAPK8 P45983 1/20 0.37
MAPK9 P45984 1/20 0.37
CDK7 P50613 1/20 0.37
CDK9 P50750 1/20 0.37
RPS6KA3 P51812 1/20 0.37
CDK5 Q00535 1/20 0.37
PTK2 Q05397 1/20 0.37
CAMK1D Q8IU85 1/20 0.37
CLK4 Q9HAZ1 1/20 0.37
ALK Q9UM73 1/20 0.37
DYRK1B Q9Y463 1/20 0.37
MEN1 O00255 4/20 0.36
KMT2A Q03164 4/20 0.36
SMN1; SMN2 Q16637 3/20 0.36
LMNA P02545 2/20 0.36
MAPT P10636 2/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL341998 0.81 SMN1; SMN2 (0.40) CSF1RLTKMAPK8MAPK9CDK7
SCHEMBL4396930 0.77 EGFR (0.41) SRCBTKCSF1RLTKMAPK8
SCHEMBL13545890 0.74 AURKA (0.42) SRCBTKMAPK8PLA2G7ALDH1A1
SCHEMBL4595519 0.72 KMT2A (0.42) SRCBTKCDK9CDK5MEN1
SCHEMBL2066542 0.72 KMT2A (0.40) SRCBTKCSF1RLTKMAPK8
SCHEMBL23588568 0.71 ESR1 (0.40) MEN1KMT2ASMN1; SMN2LMNAMAPT
SCHEMBL20476331 0.70 ESR1 (0.47) KMT2ALMNAMAPTEGFRESR2
SCHEMBL18063507 0.69 PDE4B (0.45) MEN1KMT2ALMNAMAPTTP53
SCHEMBL11919247 0.69 ALDH1A1 (0.42) SRCBTKCSF1RLTKMAPK8
SCHEMBL4397422 0.69 KMT2A (0.51) CSF1RLTKMAPK8MAPK9CDK7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090306116-A1 PYRIMIDINE DERIVATIVES FOR THE INHIBITION OF IGF-IR TYROSINE KINASE ACTIVITY ASTRAZENECA AB (SE) 2009-12-10 US disclosed
CN-101304996-A Pyrimidine Derivatives Inhibiting IGF-1R Tyrosine Kinase Activity ASTRAZENECA AB (SE) 2008-11-12 CN disclosed
EP-1931662-A1 PYRIMIDINE DERIVATIVES FOR THE INHIBITION OF IGF-IR TYROSINE KINASE ACTIVITY AstraZeneca AB (SE) 2008-06-18 EP disclosed
WO-2007031745-A1 PYRIMIDINE DERIVATIVES FOR THE INHIBITION OF IGF-IR TYROSINE KINASE ACTIVITY ASTRAZENECA AB (SE) 2007-03-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090306116-A1 PYRIMIDINE DERIVATIVES FOR THE INHIBITION OF IGF-IR TYROSINE KINASE ACTIVITY IGF1R, IGFBP1, IRS1 SRC 189/4885BTK 89/4885CSF1R 80/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.